Literature DB >> 7843260

Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors.

K Svensson1, A Carlsson, R M Huff, T Kling-Petersen, N Waters.   

Abstract

In an in vitro model for mitogenic activity in cloned Chinese hamster ovary (CHO) cells expressing rat dopamine D2 or D3 receptors, the EC50D2/EC50D3 ratios for the agonists, apomorphine, (+)-3-hydroxy-N-n-propyl-phenylpiperidine ((+)-3-PPP), quinpirole, R-(+)-7-hydroxy-2-(di-n-propylamino)tetralin (R-(+)-7-OH-DPAT) and pramipexole (SND919) were found to be 0.36, 0.41, 1.3, 3.7 and 7.0, respectively. In locomotor activity experiments with actively exploring rats, the more dopamine D3 preferring agonists, R-(+)-7-OH-DPAT and pramipexole, were most efficacious to reduce locomotion. The hypoactivity was also observed at doses that did not affect brain dopamine synthesis rate (DOPA accumulation) or release (measured in in vivo dialysis experiments). In contrast, for apomorphine, (+)-3-PPP and quinpirole there was a closer correlation between doses that reduced exploratory activity and doses that reduced brain dopamine release and synthesis. The present data support the hypothesis that the functional dopamine D3 receptor is a postsynaptic receptor inhibitory on rat locomotion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843260     DOI: 10.1016/0014-2999(94)90718-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  27 in total

1.  Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.

Authors:  Martin Weber; Wei-Li Chang; John P Durbin; Paula E Park; Robert R Luedtke; Robert H Mach; Neal R Swerdlow
Journal:  Pharmacol Biochem Behav       Date:  2009-05-06       Impact factor: 3.533

2.  Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat.

Authors:  T Kling-Petersen; E Ljung; L Wollter; K Svensson
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Antipsychotics with inverse agonist activity at the dopamine D3 receptor.

Authors:  N Griffon; C Pilon; F Sautel; J C Schwartz; P Sokoloff
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats.

Authors:  Wei-li Chang; Neal R Swerdlow; Michelle R Breier; Niveditha Thangaraj; Martin Weber
Journal:  Pharmacol Biochem Behav       Date:  2010-04-10       Impact factor: 3.533

5.  Antidepressant effects of pramipexole, a novel dopamine receptor agonist.

Authors:  J Maj; Z Rogóz; G Skuza; K Kołodziejczyk
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

6.  The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.

Authors:  Wei-Li Chang; Mark A Geyer; Mahalah R Buell; Martin Weber; Neal R Swerdlow
Journal:  Behav Pharmacol       Date:  2010-03       Impact factor: 2.293

7.  Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.

Authors:  P A Broderick; L Wenning; Y-S Li
Journal:  J Neural Transm (Vienna)       Date:  2016-10-28       Impact factor: 3.575

8.  Differential susceptibility to ethanol and amphetamine sensitization in dopamine D3 receptor-deficient mice.

Authors:  Sarah Jane Harrison; José N Nobrega
Journal:  Psychopharmacology (Berl)       Date:  2008-12-19       Impact factor: 4.530

9.  D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons.

Authors:  Yun Wang; Patricia S Goldman-Rakic
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

10.  Pramipexole effects on startle gating in rats and normal men.

Authors:  Neal R Swerdlow; Sophia A Lelham; Ashley N Sutherland Owens; Wei-Li Chang; Sebastiaan D T Sassen; Jo A Talledo
Journal:  Psychopharmacology (Berl)       Date:  2009-06-09       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.